Behaviour · Children and adolescents (0 to 16 years) needing dental treatment
1 finding from 1 review
Behaviour · Children and adolescents (0 to 16 years) needing dental treatment
It is very uncertain whether intravenous midazolam changes behaviour (Houpt/behavioural score) compared with placebo (including no intervention) (very low certainty).
1 finding from 1 review
Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Glutamine (intravenous) led to lower oral mucositis (severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Locoregional control · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine (intravenous) showed no clear difference in locoregional tumour control compared with amifostine (subcutaneous); GRADE not reported.
1 finding from 1 review
HR 1.34 [0.76, 2.36]
1 study
GRADE not reported
Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Overall survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine (intravenous) showed no clear difference in overall survival compared with amifostine (subcutaneous); GRADE not reported.
1 finding from 1 review
HR 1.36 [0.89, 2.10]
1 study
GRADE not reported
Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Xerostomia (grade >= 2, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine (intravenous) led to lower xerostomia (grade >= 2, 0-4 scale) compared with amifostine (subcutaneous); GRADE not reported.
2 findings from 1 review
Amount of analgesia · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
None of the prophylactic aciclovir versus placebo trials reported on amount of analgesia. For prevention or treatment, no trials reported on duration of hospital stay, amount of analgesia or patient quality of life.
0 studies
No studies found
Patient quality of life · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
None of the prophylactic aciclovir versus placebo trials reported on patient quality of life. For prevention or treatment, no trials reported on duration of hospital stay, amount of analgesia or patient quality of life.
0 studies
No studies found
Viral isolates (HSV isolates identified, with or without clinical symptoms) · Patients being treated for cancer (predominantly haematological malignancies)
Prophylactic aciclovir (oral or intravenous) led to lower viral isolates (HSV isolates identified, with or without clinical… compared with placebo; GRADE not reported.
1 finding from 1 review
Presence/absence of HSV oral lesions · Patients being treated for cancer (predominantly haematological malignancies)
Prophylactic aciclovir (oral or intravenous) showed no clear difference in presence/absence of HSV oral lesions compared with prophylactic valaciclovir (oral); GRADE not reported.
1 finding from 1 review
Presence/absence of HSV oral lesions · Patients being treated for cancer (predominantly haematological malignancies)
Prophylactic aciclovir (oral or intravenous) led to lower presence/absence of HSV oral lesions compared with placebo; GRADE not reported.
1 finding from 1 review
Length of hospital stay · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
Recurrence of lesions · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
Cost of oral care · Patients being treated for cancer (predominantly haematological malignancies)
1 finding from 1 review
Only one trial reported on the cost of prophylaxis for HSV (Liesveld 2002). The reported mean pharmacy costs for those randomised to receive aciclovir were $1080 compared to $320 for those initially randomised to…
1 study · 30 participants
GRADE not reported
Adverse effects · Patients being treated for cancer (predominantly haematological malignancies)
1 finding from 1 review
Oral mucositis (any severity) · Children with acute lymphoblastic leukaemia receiving chemotherapy alone
Keratinocyte growth factor (KGF), intravenous led to lower oral mucositis (any severity) compared with chlorhexidine mouthwash; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Children with acute lymphoblastic leukaemia receiving chemotherapy alone
Keratinocyte growth factor (KGF), intravenous led to lower oral mucositis (moderate to severe) compared with chlorhexidine mouthwash; GRADE not reported.
1 finding from 1 review